Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
A hypochlorite-activated strategy for realizing fluorescence turn-on, type I and type II ROS-combined photodynamic tumor ablation — Tonghui Huang (2023) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
A hypochlorite-activated strategy for realizing fluorescence turn-on, type I and type II ROS-combined photodynamic tumor ablation
BT
Shared by
Ben Zhong Tang
A hypochlorite-activated strategy for realizing fluorescence turn-on, type I and type II ROS-combined photodynamic tumor ablation
Article
2023
en
Authors
+5 more
TH
Tonghui Huang
HJ
Heng Ji
SY
Shirong Yan
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Corrigendum
2023
Corrigendum to A hypochlorite-activated strategy for realizing fluorescence turn-on, type I and type II ROS-combined photodynamic tumor ablation Biomaterials Volume 297, 122108, (2023)
Tonghui Huang
,
Heng Ji
,
Shirong Yan
,
Yifan Zuo
,
Jie Li
,
Jacky W. Y. Lam
,
Cuiping Han
,
Ben Zhong Tang
Article
2021
Cationization to boost both type I and type II ROS generation for photodynamic therapy
Yuewen Yu
,
Shuang Wu
,
Le Zhang
,
Shidang Xu
,
Chunhui Dai
,
Shengming Gan
,
Ganfeng Xie
,
Guangxue Feng
,
Ben Zhong Tang
Article
2022
Cationization-Enhanced Type I and Type II ROS Generation for Photodynamic Treatment of Drug-Resistant Bacteria
Shanshan Liu
,
Bingnan Wang
,
Yuewen Yu
,
Yubo Liu
,
Zeyan Zhuang
,
Zujin Zhao
,
Guangxue Feng
,
Anjun Qin
,
Ben Zhong Tang
Article
2023
Multifunctional nanomicelles constructed <i>via</i> an aggregation and de-aggregation strategy for magnetic resonance/NIR II fluorescence imaging-guided type I photodynamic therapy
Lirong Wang
,
Ji Qi
,
Ke Zhang
,
Zeyan Zhuang
,
Keke Ding
,
Xu Chen
,
Hong Shan
,
Dan Ding
,
Anjun Qin
,
Ben Zhong Tang
Article
2016
Use of fluorescent probes for ROS to tease apart Type I and Type II photochemical pathways in photodynamic therapy
María García-Díaz
,
Ying‐Ying Huang
,
Michael R Hamblin
Discussion(0)
No comments yet. Be the first to comment.